^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Hansoh Xinfu (flumatinib) (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3171 Evaluating Effectiveness and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia in (CML-CP) without Optimal Response (Warning, Failure) to Imatinib or/and Dasatinib
Published date:
11/02/2023
Excerpt:
Switching to flumatinib from imatinib or/and dasatinib have been reported with an enhanced optimal molecular response in patients who experienced warning compared with those who had treatment failure after the TKIs with 38 (100%) vs 38 (79%), 29 (91%) vs 23 (59%) and 15 (68%) vs 10 (42%) at 3-, 6- and 12-months respectively...For Ph+ CML-CP patients without the optimal molecular response in previous imatinib or/and dasatinib, flumatinib is a better alternative to the existing treatments. In addition, if the patients were switched to flumatinib earlier, the optimal response was achieved faster.
